Wed, Oct 22, 2014, 6:17 AM EDT - U.S. Markets open in 3 hrs 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • nuselrami nuselrami Jun 21, 2013 4:46 PM Flag

    it is clear now- it is all about management!

    The investors do not buy management presentations any more. There is no other explanation for the stock price with last days impressive news...PLX board has to understand that without proper management the company will go nowhere... This management apparently lost its credit by investors although we have FDA approval and even a deal in Brazil... I noticed the big conditions of this deal the payment to PFE and the finders 5% payment but still this is a good start... so why investors are not buying? because they don't trust management- this is my opinion about the poor share performance...and lastly- they need to bring in partners because the company can't develop these potential drugs without big money! the fact that we do not see any partners with money is a very bad sign! I am holding this share directly and indirectly for about 15 years before they became public, i had orzit and than biosel and than PLX- something is very wrong with the current management! it looks they lost faith by investors, not only small but big investors too. I hope I am wrong!!
    If they bring in somebody known from the industry with relevant experience the change may come.... if not we will have to wait for few years before we see anything as far as increase in the share price. A PLATFORM COMPANY WITH FDA APPROVAL AND PIPELINE OF SEVERAL DRUGS WORTH MUCH MORE THAN CURRENT PRICE AND PLX MANAGEMENT KNOWS THAT VERY WELL BUT THE REASON IS IN THEM!

 
PLX
2.36-0.08(-3.28%)Oct 21 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.